Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 3(2)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02235272Phase 3Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Role: lead

NCT02508337Phase 3Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

Role: lead

NCT02235259Phase 2Completed

Efficacy and Safety of XG-104 for the Treatment of Dry Eye

Role: lead

NCT01570205Phase 1Completed

Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers

Role: lead

All 4 trials loaded